AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 231 min read$GERN

Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

Analysts commented on Geron (GERN) and Fair Isaac (FICO). H.C. Wainwright maintained a Hold rating on GERN with a $1.50 target, while Wells Fargo reiterated a Buy on FICO with a $1350 target. GERN has a Strong Buy consensus and 233.1% upside, FICO has a Moderate Buy consensus and 56.3% upside.

Original reporting
theglobeandmail.com
Published Sep 23, 2026, 10:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$GERNNeutralLow
01

Why it matters

Analyst rating reiterations provide modest guidance but lack fresh material; limited trading impetus.

02

Market read

Analyst commentary offers slight directional bias but no actionable catalyst.

03

What to watch

Absence of earnings or news means price targets rely on assumptions rather than new data.

Relevance 4/10Novelty 2/10Timing: today

Background

The article aggregates analyst opinions on Geron and Fair Isaac without reporting new corporate events.

Company-level read

Ticker impact

$GERNNeutralMedium confidence
Context

Analyst maintained Hold rating and cited price target of $1.50, no new corporate event.

Expected impact

Limited impact; price may stay range-bound.

Evidence & confidence

Rating unchanged and target modestly above current price; unlikely to trigger large moves.

$FICOBullishMedium confidence
Context

Analyst reiterated Buy rating and set $1,350 target, no new company action disclosed.

Expected impact

Potential modest upside if investors follow target.

Evidence & confidence

Upward target may attract interest but lacks fresh catalyst.

Market effects

Sector

Both firms are in niche finance/healthcare sectors; analyst coverage may slightly influence sector sentiment.

Regional

North American market focus; minimal broader regional effect.

Global

Limited global relevance.

Counterpoint

What could challenge this read

Ratings unchanged may suggest stagnation; investors could wait for a catalyst.

Key entities

  • Company
    Geron

    Biotech firm GERN

  • Company
    Fair Isaac

    Analytics firm FICO

Read at source← All news

Related articles

OCT 28
$GERNHighAI 8/10

Why is Geron stock sliding today?

Geron (GERN) stock fell 10.4% to $1.03 after halting a Phase 3 trial for imetelstat in myelofibrosis patients due to low likelihood of meeting the primary survival endpoint. The trial's discontinuation is a strategic setback, as the indication was a key growth opportunity. The stock was already near its 52-week low, and the move was driven by company-specific news, with no broader market impact.

investing.com2 min
OCT 28
$GERNLow

Geron stock tumbles after halting Phase 3 trial

Geron (GERN) shares dropped 12% after halting a Phase 3 trial for imetelstat in myelofibrosis. The decision followed a DMC recommendation that the trial was unlikely to meet its primary survival endpoint. The company plans to analyze data and share findings later. Geron remains focused on its commercial business and RYTELO demand.

investing.com1 min
OCT 28
$GERNMedAI 8/10

A blood cancer trial is set to stop after monitors say it is unlikely to meet its survival goal.

Geron Corporation (GERN) will discontinue its Phase 3 IMpactMF trial for imetelstat in myelofibrosis after the Data Monitoring Committee advised it was unlikely to meet the primary survival endpoint. The company will analyze the data and share findings later. Geron remains focused on its commercial business and growing demand for RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).

stocktitan.net5 min